Hanmi Pharmaceutical said Wednesday that its partner, MSD, has obtained marketing approval from Mexico’s Federal Committee for Protection from Sanitary Risks for its dyslipidemia drug, Rosuzet, with the localized name of Naxzalla.

Rosuzet is a novel drug for treating dyslipidemia developed by Hanmi. It is a blockbuster drug that recorded the largest sales of outpatient prescriptions among new drug compounds developed by the domestic pharmaceuticals. It combined two components that treat dyslipidemia, rosuvastatin, and ezetimibe, the company said.

The drug induces dual inhibition of cholesterol synthesis and absorption in the liver and small intestine, lowering low-density lipoprotein cholesterol (LDL-C) in the blood.

Hanmi Pharmaceutical is expanding the overseas shipments of its flagship product, signing a global export contract of Rosuzet to 23 countries with MSD.

“Rosuzet has a solid advantage in the domestic dyslipidemia drug market based on its excellent quality and many clinical cases,” Hanmi Pharmaceutical CEO Woo Jong-soo said. “We will expand the exports of competitive products based on our excellent formulation technology.”

According to UBIST data, Rosuzet has been the top outpatient prescription in the statin and ezetimibe combination market since November 2017. It also ranked second among all dyslipidemia treatments, with sales of 22.8 billion won ($19 million) in the first quarter of 2020.